Palisade Bio reports early Phase 1b reductions in inflammation and endoscopic disease activity for PALI‑2108
Palisade Bio presented data from a five‑patient open‑label Phase 1b study of its oral PDE4 inhibitor prodrug PALI‑2108 in fibrostenotic Crohn’s disease. After 14 days, the mean fecal calprotectin level fell 58.8 % and the mean Simple Endoscopic Score for Crohn’s Disease dropped 47.5 %. Two of the five participants showed an endoscopic response, and another two met criteria for endoscopic remission. The company said the results are preliminary, that safety was favorable, and that it is enrolling a Phase 2b ulcerative colitis trial and starting a Phase 2a Crohn’s study.
Why it matters
The company’s stock rose about 9 % after the announcement, reflecting investor optimism about the early signals. The data provide the first human evidence of target engagement and anti‑inflammatory activity for PALI‑2108, which could influence the valuation of Palisade’s pipeline if later‑stage trials confirm efficacy.
Key facts
- 1The Phase 1b Crohn’s cohort included five patients with fibrostenotic disease and a mean disease duration of 15.4 years. stocktitan.net
- 2Mean fecal calprotectin decreased by 58.8 % from baseline after 14 days of treatment. stocktitan.net
- 3Mean Simple Endoscopic Score for Crohn’s Disease fell by 47.5 %. stocktitan.net
- 4Two of the five participants showed an endoscopic response, and another two met criteria for endoscopic remission. stocktitan.net
- 5All adverse events reported in the Crohn’s cohort were mild; no serious events or discontinuations occurred. stocktitan.net
- 6Palisade is enrolling a Phase 2b ASCENTRA‑UC study in ulcerative colitis and initiating a Phase 2a open‑label study in Crohn’s disease. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.